Across TCGA pan-cancer cohorts, MGLL Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MGLL data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher MGLL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MGLL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
SKCM, UCEC, and STAD are the cancer types where MGLL Mutation most reproducibly stratifies survival.